Evenity (Romosozumab) and SSRIs (Sertraline, Escitalopram) Interaction

What Is the Interaction Between Romosozumab and SSRIs?

The interaction between romosozumab and SSRIs (sertraline, escitalopram) is pharmacodynamic rather than pharmacokinetic. Romosozumab is a monoclonal antibody cleared by proteolytic degradation, not by hepatic CYP enzymes or P-glycoprotein, so SSRIs do not alter its plasma concentration or half-life. The real clinical issue is that SSRIs actively reduce bone mineral density (BMD) through serotonin signaling in osteoblasts and osteoclasts, which may partially oppose the anabolic gains romosozumab is prescribed to produce.

A second, separate concern applies specifically to escitalopram: dose-dependent QTc prolongation that could compound the cardiovascular risk already flagged in romosozumab's FDA black-box warning.

Pharmacokinetics: Why CYP Interactions Do Not Apply

Romosozumab is an IgG2 monoclonal antibody with a mean half-life of approximately 6.9 days after subcutaneous injection [1]. Like all large-molecule biologics, it is catabolized by the reticuloendothelial system into peptide fragments and amino acids. It does not undergo CYP1A2, CYP2D6, CYP3A4, or CYP2C19-mediated hepatic metabolism, and it is not a P-glycoprotein substrate [1].

Sertraline is a CYP2D6 inhibitor and a moderate CYP2C9 inhibitor [2]. Escitalopram is a mild CYP2D6 inhibitor and a QTc-prolonging agent at doses above 20 mg/day [3]. Neither of those properties has any enzymatic target in romosozumab's elimination pathway.

The FDA label for Evenity lists no specific drug interactions requiring dose adjustment [1]. The FDA label for escitalopram explicitly lists the QTc risk and warns against combination with other QTc-prolonging agents [3].

Pharmacodynamics: How SSRIs Reduce Bone Density

Serotonin receptors are expressed on osteoblasts, osteoclasts, and osteocytes [4]. Peripheral serotonin (synthesized in the gut) suppresses bone formation; SSRIs block the serotonin transporter (SERT) in osteoblasts and disrupt serotonin-mediated anabolic signaling in bone [4]. The net effect across multiple cohort studies is a measurable reduction in BMD at the lumbar spine and femoral neck.

In a prospective cohort study of 5,995 older adults (Women's Health Initiative substudy), SSRI users showed approximately 0.82% greater annual bone loss at the hip compared with non-users [5]. A meta-analysis of 10 observational studies including more than 600,000 participants found SSRI users had approximately a 1.7-fold higher risk of hip fracture (relative risk 1.72, 95% CI 1.51 to 1.97) compared with non-users [6]. That fracture risk operates independently of fall risk from SSRI-related sedation or orthostatic hypotension.

Romosozumab in the FRAME trial (N=7,180) produced a 13.3% increase in lumbar spine BMD and a 6.9% increase at the total hip at 12 months vs. 0.0% and 0.5% with placebo, respectively [7]. If an SSRI is simultaneously reducing BMD at roughly 0.5 to 1.0% per year, the net clinical gain from romosozumab may be attenuated, though no head-to-head trial has directly quantified this offset.

Cardiovascular Risk: The Escitalopram-Specific Concern

Romosozumab carries an FDA black-box warning for major adverse cardiovascular events (MACE), specifically myocardial infarction and stroke. In the ARCH trial (N=4,093), romosozumab followed by alendronate produced a higher rate of cardiovascular serious adverse events compared with alendronate alone (2.5% vs. 1.9%) at 12 months [8]. The prescribing information contraindicates use in patients who have experienced MI or stroke within the previous 12 months [1].

Escitalopram independently prolongs the QTc interval in a dose-dependent manner. The FDA issued a safety communication in 2011 and updated the escitalopram label to state that doses above 20 mg/day are not recommended due to QTc risk [3]. A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) confirmed escitalopram's disproportionate association with torsades de pointes signals among antidepressants [9].

When Both Risks Converge

A postmenopausal woman with severe osteoporosis and depression is a common clinical profile. If she has a prior cardiac history, romosozumab is already contraindicated regardless of her antidepressant regimen. If she is cardiac-risk-free but takes escitalopram at 20 mg/day or higher, a baseline ECG is warranted before starting romosozumab injections, and the escitalopram dose should be reviewed to confirm the minimum effective level is being used [3].

Sertraline has a substantially lower QTc signal than escitalopram. A network meta-analysis of antidepressant cardiac safety found sertraline's mean QTc change was approximately 1.2 ms vs. Escitalopram's 10.7 ms at standard doses [10]. For patients on escitalopram, discussing a switch to sertraline with the treating psychiatrist is a reasonable conversation when romosozumab is being initiated, though clinical continuity and psychiatric stability should guide any such decision.

Monitoring Protocol for Co-administration

Patients receiving romosozumab alongside any SSRI should have:

• A baseline DXA scan at lumbar spine and total hip before the first injection, with follow-up DXA at 12 months (end of the romosozumab course).
• A standard metabolic panel including serum calcium and 25-hydroxyvitamin D before injection one, because romosozumab transiently increases bone formation markers within the first few months [1].
• Baseline ECG if escitalopram is prescribed, with particular attention to the corrected QT interval; follow-up ECG if the escitalopram dose increases during the romosozumab course.
• Blood pressure monitoring at each monthly injection visit, given overlap of SSRI-associated orthostatic hypotension and cardiovascular surveillance for romosozumab.

SSRI Effects on Bone: The Broader Clinical Picture

Serotonin Transporter Signaling in Osteoblasts

The molecular mechanism linking SSRIs to bone loss centers on SERT expression in osteoblast precursors. Peripheral serotonin acts as a paracrine inhibitor of osteoblast proliferation through the 5-HT1B receptor [4]. When SSRIs block SERT on osteoblasts, intracellular serotonin accumulates and the 5-HT1B-mediated suppression of CREB (cAMP response element-binding protein) activation increases, reducing osteoblast differentiation and bone matrix synthesis [4]. Animal data using SERT-knockout mice confirmed a low-bone-mass phenotype, supporting the causal direction of this pathway [11].

Epidemiological Fracture Data

Three large observational datasets converge on a meaningful fracture signal with chronic SSRI use:

• A case-control study of 124,655 fracture cases in the UK Clinical Practice Research Datalink found current SSRI use was associated with an adjusted odds ratio of 1.34 (95% CI 1.28 to 1.41) for any fracture [12].
• The Canadian Multicentre Osteoporosis Study found SSRI users had 2.1% lower femoral neck BMD at baseline compared with non-users after adjusting for age, BMI, and physical activity [13].
• A 2023 systematic review in the Journal of Bone and Mineral Research (26 studies, N approximately 1.2 million) reported a pooled relative risk of 1.46 (95% CI 1.32 to 1.61) for any fracture in SSRI users vs. Controls [14].

Duration of SSRI Use Matters

Short-term SSRI use (fewer than 90 days) shows minimal BMD impact in most cohort data. Bone loss becomes statistically detectable at 6 months of continuous use and is most pronounced after 12 months or more [5]. Patients who have taken sertraline or escitalopram for over a year before starting romosozumab may be starting from a lower BMD baseline than would be expected from their age and fracture history alone. Ordering a DXA scan before the first romosozumab injection rather than relying on older imaging is sound practice in this subgroup.

Romosozumab Mechanism and Why It Matters for This Interaction

Romosozumab binds sclerostin, a Wnt pathway inhibitor secreted by osteocytes. Blocking sclerostin allows Wnt ligands to activate LRP5/6 receptors on osteoblast precursors, increasing osteoblast differentiation and bone matrix deposition while simultaneously reducing RANKL-driven osteoclast activation [7]. The result is a dual anabolic-antiresorptive effect unique among approved osteoporosis therapies.

The Bone Formation Window

The anabolic effect of romosozumab is front-loaded. Bone formation markers (P1NP) peak at month one and return toward baseline by month nine of a 12-month course, even as antiresorptive effects persist [7]. This means the highest-value months for romosozumab's bone-building activity occur early in the treatment course, precisely when any SSRI-mediated suppression of osteoblast activity is also ongoing.

If an SSRI cannot be discontinued, optimizing the anabolic window with adequate calcium (1,200 mg/day elemental, split doses) and vitamin D (800 to 2,000 IU/day targeting serum 25-OHD above 30 ng/mL) becomes especially important [15]. The American Association of Clinical Endocrinology 2020 guidelines state: "All patients receiving pharmacologic therapy for osteoporosis should achieve adequate calcium and vitamin D intake to maximize treatment efficacy" [16].

Transitioning After Romosozumab

The 12-month romosozumab course must be followed by antiresorptive therapy to preserve gains. In the FRAME trial, patients who transitioned to denosumab at month 12 maintained a 21.0% lumbar spine BMD gain at 24 months, while those who did not received further anabolic therapy showed partial reversal [7]. If SSRIs continue post-romosozumab, the antiresorptive bridge (typically alendronate 70 mg weekly or denosumab 60 mg every 6 months) is not optional. Discontinuing antiresorptive therapy after romosozumab in an SSRI user would combine two simultaneous causes of bone loss.

Patient Counseling: Practical Points

Clinicians prescribing romosozumab alongside an SSRI should cover five specific topics with the patient:

1. Why the SSRI matters for bone. Explain that antidepressants like sertraline and escitalopram can slow bone-building in a measurable way, which is why serial DXA scans are scheduled.

2. Calcium and vitamin D are not optional. The bone-anabolic window for romosozumab is approximately the first six months of the 12-month course. Consistent calcium and vitamin D supplementation during this period may help offset the SSRI effect [15].

3. Heart safety with escitalopram. If the patient takes escitalopram above 20 mg/day, explain the ECG requirement before injections begin. This is a brief, low-burden check that prevents a meaningful cardiac risk [3].

4. The monthly injection schedule is fixed. Romosozumab is dosed as two 105 mg subcutaneous injections (total 210 mg) administered consecutively once monthly for 12 months [1]. Missed injections should be given as soon as possible and the schedule reset from that date.

5. What happens after 12 months. Patients stopping SSRIs after romosozumab is complete still need antiresorptive therapy. Those continuing SSRIs need it even more urgently.

The FDA label for Evenity states: "Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate" and specifies monitoring for hypocalcemia before each dose in patients with severe renal impairment [1].

Severity Classification and Prescribing Decision

Across standard DDI databases (Lexicomp, Clinical Pharmacology, Micromedex), the romosozumab-SSRI combination is typically rated as a moderate interaction based on the pharmacodynamic bone-loss signal, not as a contraindication [17]. No DDI database rates this combination as requiring automatic avoidance.

The cardiovascular overlay with escitalopram elevates the clinical complexity to a level warranting prescriber review at the time of initiation, but again does not constitute a contraindication in cardiac-healthy patients. Sertraline's lower QTc burden makes it the preferable SSRI from a cardiac-safety standpoint when an antidepressant is required during a romosozumab course [10].

A reasonable prescribing hierarchy looks like this:

• Preferred: Sertraline at the lowest effective dose, with baseline and 12-month DXA, adequate calcium and vitamin D, and standard monthly monitoring visits.
• Acceptable with additional monitoring: Escitalopram at or below 20 mg/day, with baseline ECG, repeat ECG at any dose increase, and the DXA and supplement protocol above.
• Requires cardiology review: Escitalopram above 20 mg/day in a patient with any pre-existing cardiac conduction abnormality or multiple cardiovascular risk factors.
• Contraindicated combination: Romosozumab in any patient (regardless of SSRI use) who has had MI or stroke within the prior 12 months [1].

The AACE 2020 Osteoporosis Clinical Practice Guidelines (Camacho et al.) specify that clinicians should "identify and address secondary causes of osteoporosis, including medications that impair bone health, before and during anabolic therapy" [16]. SSRIs fall within that category and should be documented in the patient's chart as an active bone-health consideration throughout the romosozumab course.

Order the 12-month follow-up DXA before the final romosozumab injection so results are available for the antiresorptive transition conversation at month 12.